NCT05923190View on ClinicalTrials.gov

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2029

Conditions
Urothelial CarcinomaMetastatic Urothelial CarcinomaLocally Advanced Urothelial Carcinoma
Interventions
DRUG

Enfortumab vedotin

EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles

DRUG

Pembrolizumab

Pembrolizumab will be administered on day 1 of a 21-day cycle

Trial Locations (1)

19111-2497

RECRUITING

Fox Chase Cancer Center - Philadelphia, Philadelphia

All Listed Sponsors
lead

Fox Chase Cancer Center

OTHER